In a phase III trial of 584 patients with HER2‐positive esophageal cancer, the median overall survival after trastuzumab treatment combined with chemoradiotherapy was longer than that of the patients who received only chemoradiotherapy.2 The gene discussed is ERBB2; the disease is esophageal cancer.